Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Zai Lab Limited ZLAB
$33.27
-$3.09 (-9.30%)
На 18:00, 12 мая 2023
+203.58%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3581500392.00000000
-
week52high
53.95
-
week52low
20.98
-
Revenue
215040000
-
P/E TTM
-9
-
Beta
1.15259500
-
EPS
-4.57000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 08:00
Описание компании
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 09 авг 2022 г. |
| Citigroup | Buy | Buy | 12 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 21 апр 2022 г. |
| JP Morgan | Overweight | Overweight | 04 апр 2022 г. |
| Citigroup | Buy | Buy | 11 ноя 2022 г. |
| JP Morgan | Overweight | Overweight | 18 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Amado Rafael | A | 183700 | 183700 | 30 дек 2022 г. |
| Amado Rafael | A | 126000 | 126000 | 30 дек 2022 г. |
| Reinhart Harald | D | 18958 | 5903 | 30 дек 2022 г. |
| WIRTH PETER | D | 0 | 4000 | 08 дек 2022 г. |
| WIRTH PETER | D | 342763 | 3852 | 08 дек 2022 г. |
| Reinhart Harald | D | 11480 | 1854 | 15 ноя 2022 г. |
| Reinhart Harald | D | 24861 | 100 | 15 ноя 2022 г. |
| Reinhart Harald | D | 24961 | 1754 | 15 ноя 2022 г. |
| Reinhart Harald | A | 26715 | 1854 | 15 ноя 2022 г. |
| Edmondson Frazor Titus III | D | 14550 | 4850 | 17 авг 2022 г. |
Новостная лента
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
GlobeNewsWire
20 апр 2023 г. в 07:30
Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET
1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off
The Motley Fool
26 мар 2023 г. в 07:45
Zai Lab will soon launch a handful of new medicines in China. It's also seeking approval for many of its therapies in the U.S. The company also has enough cash to survive even if some of its clinical trials fail.
2 Growth Stocks With Incredible Potential in the Next 5 Years
The Motley Fool
06 мар 2023 г. в 08:30
Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy.
3 More Mid-Cap Biotechs The Street Sees Doubling
MarketBeat
22 февр 2023 г. в 08:46
Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the lives of millions of patients with a wide range of diseases.
Zai Lab Limited (ZLAB) Presents at Citi Biotech C-Suite Fireside Chat Series Conference (Transcript)
Seeking Alpha
14 февр 2023 г. в 15:23
Zai Lab Limited (NASDAQ:ZLAB ) Citi Biotech C-Suite Fireside Chat Series Conference Call February 14, 2023 11:00 AM ET Company Participants Josh Smiley - COO Conference Call Participants Yigal Nochomovitz - Citi Yigal Nochomovitz Okay, great. I'm Yigal Nochomovitz.